TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)

Launched by JENSCARE INNOVATION INC. · Aug 20, 2024

Keywords

ClinConnect Summary

The TRINITY-US clinical trial is studying a new treatment called the LuX-Valve Plus System for patients with severe tricuspid regurgitation (TR), a condition where the heart's tricuspid valve doesn't close properly, allowing blood to flow backward. This trial is specifically for patients who are showing symptoms and are considered too high-risk for traditional surgery. The goal is to evaluate how safe and effective this new system is for these patients.

To be eligible for the trial, participants need to be at least 18 years old and have been diagnosed with severe TR. They should be experiencing moderate to severe symptoms that affect their daily life, as defined by a specific heart health classification. The doctors involved in the study must agree that surgery is not a suitable option for them. Participants will need to provide informed consent, meaning they understand the study and agree to take part. If you or someone you know is interested, it’s important to discuss with a healthcare provider to see if this trial might be a good fit.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years at time of consent
• • Severe or greater TR assessed on transthoracic echocardiography by Echocardiography Core Lab using a 5-grade classification (Mild, Moderate, Severe, Massive, Torrential).
• • New York Heart Association (NYHA) Class II-IV
• • The Patient is being treated on optimal dosage for diuretics at investigator discretion
• • The Site Heart Team concur the patient is not an optimal candidate for surgical treatment and it is anatomically suitable for transcatheter tricuspid valve replacement
• • Patient must be able to fully understand all aspects of the investigation that are relevant to the decision to participate and provide a written informed consent
• • Anatomical inclusion criteria confirmed by echocardiographic core lab, CT core lab and Eligibility Committee
• Exclusion Criteria:
• • Left Ventricular Ejection Fraction (LVEF) \<35%
• • Pulmonary arterial systolic pressure (PASP) \>60 mmHg by echo Doppler (unless right heart catheterization \[RHC\] demonstrates PASP ≤60mmHg); or Right heart catheterization OR PASP \>2/3 systemic BP with PVR \>5 Wood units after vasodilator challenge, in the absence of symptomatic hypotension or systolic BP \<90 mmHg.
• • Evidence of intracardiac mass, thrombus, or vegetation
• • Ebstein Anomaly or congenital right ventricular dysplasia
• • Surgical correction is indicated for other concomitant valvular disease (subjects with concomitant valvular disease may treat their respective valve first and wait 2 months before being reassessed for the trial)
• • Patients with valve prostheses implanted in the tricuspid valve
• • Pre-existing prosthetic valve(s) (other than tricuspid ones) with clinically significant prosthetic dysfunction
• • Active infection, infective endocarditis or sepsis within 3 months, or infections requiring antibiotics treatment within two weeks prior to planned procedure
• • Untreated clinically significant coronary artery disease requiring revascularization
• • Acute myocardial infarction or unstable ischemia-related angina within 30 days prior to the planned procedure
• • Any percutaneous coronary, intracardiac or carotid intervention within 30 days prior to the planned procedure
• • Any coronary or intracardiac or carotid intervention within 30 days prior to the planned procedure
• • Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support TRINITY-US Trial #: Ver 1.0, 14 Nov 2023, Confidential Page 7 of 8
• • Cerebrovascular stroke (ischemic or bleeding) within prior 3 months to enrollment
• • Active peptic ulcer or active gastrointestinal bleeding within prior 3 months to enrollment
• • Blood dyscrasias as defined: leukopenia (WBC \<1000 mm3), thrombocytopenia (platelet count \<50,000 cells/mm3), history of bleeding diathesis, or coagulopathy
• • Inability to tolerate anticoagulation or antiplatelet therapy
• • Severe liver failure
• • Renal insufficiency (eGFR \<30 mL/min \[per the Cockcroft-Gault formula\] and/or renal replacement therapy)
• • Uncontrolled atrial fibrillation (e.g., resting heart rate \>120 bpm)
• • Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements
• • Severe Chronic Obstructive Pulmonary Disease requiring steroids or requiring continuous home oxygen
• • Untreatable hypersensitivity or contraindication to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), bovine tissue, glutaraldehyde, or contrast media
• • Estimated life expectancy \<12 months.
• • Subjects currently participating in another clinical trial of an investigational drug or device that has not yet completed its primary endpoint
• • Patients with current history of illicit drug use
• • Any other condition making it unlikely the patient will be able to complete all protocol procedure and follow-ups determined by the investigator